Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Methotrexate gives durable remission from idiopathic granulomatous mastitis

Publish date:: January 13, 2020

Key clinical point: Methotrexate, in combination with prednisone, might be emerging as the go-to option for idiopathic granulomatous mastitis.

Major finding: Reported remission rates range from 75%-100%.

Study details: A single-center review of 23 patients

Disclosures: There was no external funding, and the investigators didn’t report any disclosures.

Citation:

Ringsted S et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 386.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Lupus & Connective Tissue Diseases

High-need, high-cost lupus patients described for first time,

Slow taper off antimalarial is best to avoid lupus flare during remission,

Sjögren’s symptom clusters may identify treatment options,

Transcutaneous VNS on the ear shows positive effects in lupus pilot trial,

ASSET extension supports abatacept as treatment for diffuse cutaneous systemic sclerosis,

All Specialties